Abstract The coronavirus disease 2019 (COVID-19) pandemic caused and is still causing
significant mortality and economic consequences all over the globe. As of today, there are …

Over two years into the outbreak of COVID-19, the quest for effective and economical drugs
has become starkly clear to reduce the risk of progression of coronavirus disease. A number …

Repurposing of currently available drugs is a valuable strategy to tackle the consequences
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …

The coronavirus disease 2019 (COVID-19) pandemic continues to cause significant
morbidity and mortality worldwide. Since a large portion of the world's population is currently …

Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection
and more than 4 million deaths globally (Updated information from the World Health …

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in
the coronavirus disease pandemic, drastically affecting global health and economy. Though …

Purpose The absence of specific treatments for COVID-19 leads to an intense global effort in
the search for new therapeutic interventions and better clinical outcomes for patients. This …

Objective: Antipsychotic compounds are known to induce sedation somnolence and have
expanded clinical indications beyond schizophrenia to regulatory approval in bipolar …

Commonly prescribed antidepressants may be associated with protection against severe
COVID-19. The mechanism of their action in this context, however, remains unknown. Here, I …

Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro …